EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer

Bangwei Fang, Xiaomeng Li, Ying Lu, Weiwei Ma, Hualei Gan, Tingwei Zhang, Qi Liu, Beihe Wang, Zixian Wang, Yi Zhu, Hai Zhu, Sa Xiao und 4 weitere

Journal of Clinical Investigation · 01.06.2026 · 136 (11)

DOI: 10.1172/jci201090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 07.04.2026. Verfasst von Bangwei Fang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Receptor, ErbB-3, Prostatic Neoplasms, Castration-Resistant, Antibodies, Bispecific, Immunoconjugates. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Medical Innovation Research Special Project, General Program of Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic castration-resistant prostate cancer (mCRPC) remains lethal with limited treatment options. Antibody–drug conjugates (ADCs) have emerged as a transformative class across multiple solid tumors, yet their clinical application in prostate cancer has been limited. Izalontamab brengitecan (Iza-bren; BL-B01D1) is a bispecific ADC-targeting EGFR and HER3 that has demonstrated activity in other malignancies. Here, we evaluated its therapeutic potential in the treatment of prostate cancer. Multi-omics analyses revealed frequent EGFR and HER3 expression in CRPC adenocarcinoma but not in neuroendocrine subtypes. BL-B01D1 exerted potent, target-dependent cytotoxicity in prostate cancer cell lines, xenografts, and patient-derived organoids (PDOs). We highlight a representative patient with mCRPC with high EGFR/HER3 expression whose disease rapidly and durably mounted a clinical and radiologic response to BL-B01D1, concordant with matched PDO sensitivity. Mechanistic studies identified ABCG2 upregulation as a driver of acquired resistance, with genetic or pharmacologic inhibition restoring BL-B01D1 sensitivity. Importantly, tumor tissue obtained at progression after BL-B01D1 treatment confirmed ABCG2 upregulation, validating a clinically relevant resistance mechanism. These findings support BL-B01D1 as a promising therapeutic strategy in mCRPC and indicate ABCG2 may be a rational target for overcoming resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, ErbB-3Prostatic Neoplasms, Castration-ResistantAntibodies, BispecificImmunoconjugatesMaleHumansAnimalsErbB ReceptorsMiceNeoplasm ProteinsCell Line, TumorXenograft Model Antitumor AssaysNeoplasm Metastasis

Stichwörter der Autor:innen

Clinical ResearchOncologyProstate cancer

Substanzen

Receptor, ErbB-3ErbB ReceptorsERBB3 protein, humanAntibodies, BispecificImmunoconjugatesEGFR protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Shanghai Genitourinary Cancer Institute, Shanghai, China.
  • Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education, Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shang…
  • Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Sichuan Biokin Pharmaceutical Co., Ltd. Chengdu, China.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Medical Innovation Research Special Project
  • General Program of Beijing Xisike Clinical Oncology Research Foundation
  • Special Program for Post-marketing Clinical Research of Innovative Drugs
  • Program for Professor of Special Appointment
  • Beijing Weikang Prostate Cancer Research Special Fund
  • Shanghai Shenkang Research Physician Innovation and Transformation Ability Training Project

Zitieren

APA

Fang, B., Li, X., Lu, Y., Ma, W., Gan, H., Zhang, T., Liu, Q., Wang, B., Wang, Z., Zhu, Y., Zhu, H., Xiao, S., Bian, X., Wei, G., Ye, D., & Zhu, Y. (2026). EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. Journal of Clinical Investigation, 136(11). https://doi.org/10.1172/jci201090

Vancouver

Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, et al. EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. Journal of Clinical Investigation. 2026;136(11). doi:10.1172/jci201090

BibTeX
@article{Fang2026,
  author = {Fang, Bangwei and Li, Xiaomeng and Lu, Ying and Ma, Weiwei and Gan, Hualei and Zhang, Tingwei and Liu, Qi and Wang, Beihe and Wang, Zixian and Zhu, Yi and Zhu, Hai and Xiao, Sa and Bian, Xiaojie and Wei, Gonghong and Ye, Dingwei and Zhu, Yao},
  title = {EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {11},
  doi = {10.1172/jci201090}
}
Kostenlos starten →